Last reviewed · How we verify
Topical application Tranexamic acid
Topical application Tranexamic acid is a Antifibrinolytic Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Surgical bleeding prevention, Menstrual bleeding disorders. Also known as: KAPRON (AMOUN Pharmaceutical co.).
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby reducing fibrinolysis and improving hemostasis.
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby reducing fibrinolysis and improving hemostasis. Used for Surgical bleeding prevention, Menstrual bleeding disorders.
At a glance
| Generic name | Topical application Tranexamic acid |
|---|---|
| Also known as | KAPRON (AMOUN Pharmaceutical co.) |
| Sponsor | Ain Shams University |
| Drug class | Antifibrinolytic |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
This mechanism is particularly useful in conditions where excessive bleeding is a concern, such as in surgical procedures or in patients with bleeding disorders. By inhibiting plasminogen activation, tranexamic acid helps to stabilize blood clots and prevent their breakdown.
Approved indications
- Surgical bleeding prevention
- Menstrual bleeding disorders
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma (PHASE2, PHASE3)
- "Topical Tranexamic Acid With Flap Fixation: A Novel Approach to Minimize Post-operative Drainage and Surgical Site Infection in Patients Undergoing Modified Radical Mastectomy" (NA)
- Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery (EARLY_PHASE1)
- Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (PHASE4)
- Protest Trial: TXA vs Saline (PHASE3)
- Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical application Tranexamic acid CI brief — competitive landscape report
- Topical application Tranexamic acid updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Topical application Tranexamic acid
What is Topical application Tranexamic acid?
How does Topical application Tranexamic acid work?
What is Topical application Tranexamic acid used for?
Who makes Topical application Tranexamic acid?
Is Topical application Tranexamic acid also known as anything else?
What drug class is Topical application Tranexamic acid in?
What development phase is Topical application Tranexamic acid in?
What are the side effects of Topical application Tranexamic acid?
Related
- Drug class: All Antifibrinolytic drugs
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Surgical bleeding prevention
- Indication: Drugs for Menstrual bleeding disorders
- Also known as: KAPRON (AMOUN Pharmaceutical co.)
- Compare: Topical application Tranexamic acid vs similar drugs
- Pricing: Topical application Tranexamic acid cost, discount & access